By Sabela OjeaAmneal Pharmaceuticals said the U.S. Food and Drug Administration approved its new drug application for its potassium phosphates in sodium chloride injection, available as a single-dose infusion bag. The pharmaceutical company on Monday said that the injection is a phosphorus replacement product indicated as a source of phosphorus to correct hypophosphatemia in adults and pediatric patients when oral or replacement is not possible, insufficient or contraindicated. The symptoms of hypophosphatemia, a disorder in which there is a low level of phosphate in the blood, include weakness, trouble breathing and loss of appetite. Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix(END) Dow Jones NewswiresJuly 29, 2024 16:38 ET (20:38 GMT)Copyright (c) 2024 Dow Jones & Company, Inc.

Source: Wall Street Journal July 29, 2024 20:42 UTC